Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | GLA | P06280 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | CA1 | P00915 | 14/20 | 0.51 |
| ▸ | CA2 | P00918 | 14/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | CA3 | P07451 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | CA4 | P22748 | 1/20 | 0.51 |
| ▸ | CA6 | P23280 | 1/20 | 0.51 |
| ▸ | CA5A | P35218 | 1/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.51 |
| ▸ | CA7 | P43166 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tripamide SCHEMBL49666 | 1.00 | KDM4E (0.59) | KDM4ELMNAGLAMAPTHTT | |
| SCHEMBL14394547 | 0.87 | LMNA (0.47) | KDM4ELMNAGLAMAPTHTT | |
| SCHEMBL11929104 | 0.87 | LMNA (0.47) | KDM4ELMNAGLAMAPTHTT | |
| SCHEMBL13815370 | 0.84 | KDM4E (0.47) | KDM4ELMNAGLAMAPTHTT | |
| SCHEMBL20368993 | 0.84 | KDM4E (0.44) | KDM4ELMNAGLAMAPTHTT | |
| SCHEMBL11925210 | 0.84 | KDM4E (0.47) | KDM4ELMNAGLAMAPTHTT | |
| Tripamide SCHEMBL4442559 | 0.84 | KDM4E (0.46) | KDM4ELMNAGLAMAPTHTT | |
| SCHEMBL3500995 | 0.75 | KDM4E (0.52) | KDM4ELMNAGLAMAPTHTT | |
| Clopamide SCHEMBL124598 | 0.74 | KDM4E (1.00) | KDM4ELMNAGLAMAPTHTT | |
| Clopamide SCHEMBL1650071 | 0.74 | KDM4E (1.00) | KDM4ELMNAGLAMAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8362062-B2 | Pharmaceutical compositions with improved dissolution | MCNEIL-PPC, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| EP-2339328-A2 | Pharmaceutical co-crystal compositions of celecoxib | Transform Pharmaceuticals, Inc. (US) | 2011-06-29 | — | — | EP | disclosed |
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| US-20060134198-A1 | Pharmaceutical compositions with improved dissolution | JOHNSON & JOHNSON CONSUMER INC. | 2006-06-22 | — | — | US | disclosed |
| US-20060052432-A1 | Pharmaceutical compositions with improved dissolution | TRANSFORM PHARMACEUTICALS, INC. | 2006-03-09 | — | — | US | disclosed |
| EP-1579198-A1 | PHARMACEUTICAL COMPOSITIONS WITH IMPROVED DISSOLUTION | Transform Pharmaceuticals, Inc. (US) | 2005-09-28 | — | — | EP | disclosed |
| CN-1668283-A | Pharmaceutical composition with improved dissolution | TRANSFORM PHARMACEUTICALS INC (US) | 2005-09-14 | — | — | CN | disclosed |
| EP-1515703-A1 | PHARMACEUTICAL COMPOSITIONS WITH IMPROVED DISSOLUTION | Transform Pharmaceuticals, Inc. (US) | 2005-03-23 | — | — | EP | disclosed |
| US-20050025791-A1 | Pharmaceutical compositions with improved dissolution | TRANSFORM PHARMACEUTICALS, INC. | 2005-02-03 | — | — | US | disclosed |
| WO-2004061433-A1 | PHARMACEUTICAL COMPOSITIONS WITH IMPROVED DISSOLUTION | TRANSFORM PHARMACEUTICALS, INC. (US) | 2004-07-22 | — | — | WO | disclosed |
| WO-2004026235-A2 | PHARMACEUTICAL COMPOSITIONS WITH IMPROVED DISSOLUTION | TRANSFORM PHARMACEUTICALS, INC. (US) | 2004-04-01 | — | — | WO | disclosed |
| WO-2004000284-A1 | PHARMACEUTICAL COMPOSITIONS WITH IMPROVED DISSOLUTION | TRANSFORM PHARMACEUTICALS, INC. (US) | 2003-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050025791-A1 | Pharmaceutical compositions with improved dissolution | ABCG2, SI, SLC10A2 | KDM4E 3912/4885LMNA 4001/4885GLA 1364/4885 |
| US-20060052432-A1 | Pharmaceutical compositions with improved dissolution | ABCG2, SI, SLC10A2 | KDM4E 3332/4885LMNA 3889/4885GLA 1192/4885 |
| US-20060134198-A1 | Pharmaceutical compositions with improved dissolution | ABCG2, SI, SLC10A2 | KDM4E 3332/4885LMNA 3889/4885GLA 1192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.